Published in Cancer Res on March 27, 2013
Trial Watch:: Oncolytic viruses for cancer therapy. Oncoimmunology (2014) 1.22
The "Trojan Horse" approach to tumor immunotherapy: targeting the tumor microenvironment. J Immunol Res (2014) 0.88
Myeloid-derived suppressor cells: Cellular missiles to target tumors. Oncoimmunology (2013) 0.83
Trial Watch-Oncolytic viruses and cancer therapy. Oncoimmunology (2015) 0.83
Myeloid-Derived Suppressor Cells as an Immune Parameter in Patients with Concurrent Sunitinib and Stereotactic Body Radiotherapy. Clin Cancer Res (2015) 0.80
Oncolytic Vesicular Stomatitis Virus as a Viro-Immunotherapy: Defeating Cancer with a "Hammer" and "Anvil". Biomedicines (2017) 0.79
Myeloid-derived suppressor cells as a Trojan horse: A cellular vehicle for the delivery of oncolytic viruses. Oncoimmunology (2013) 0.78
In vitro exploration of a myeloid-derived suppressor cell line as vehicle for cancer gene therapy. Cancer Gene Ther (2016) 0.78
Murine Tumor Models for Oncolytic Rhabdo-Virotherapy. ILAR J (2016) 0.77
Doxorubicin resistant cancer cells activate myeloid-derived suppressor cells by releasing PGE2. Sci Rep (2016) 0.77
Oncolytic virotherapy for urological cancers. Nat Rev Urol (2016) 0.76
Delivering safer immunotherapies for cancer. Adv Drug Deliv Rev (2017) 0.76
Immune cells: more than simple carriers for systemic delivery of oncolytic viruses. Oncolytic Virother (2015) 0.75
Tumor-specific delivery of biologics by a novel T-cell line HOZOT. Sci Rep (2016) 0.75
Taming immune suppressor: application of myeloid-derived suppressor cells in anti-cancer gene therapy. Transl Cancer Res (2017) 0.75
Cell carriers for oncolytic viruses: current challenges and future directions. Oncolytic Virother (2013) 0.75
Colonization of xenograft tumors by oncolytic vaccinia virus (VACV) results in enhanced tumor killing due to the involvement of myeloid cells. J Transl Med (2016) 0.75
Clinical Impact of the Immunome in Lymphoid Malignancies: The Role of Myeloid-Derived Suppressor Cells. Front Oncol (2015) 0.75
Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol (2008) 9.25
Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell (2004) 7.61
Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res (2006) 7.02
Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother (2008) 6.55
MyD88-dependent expansion of an immature GR-1(+)CD11b(+) population induces T cell suppression and Th2 polarization in sepsis. J Exp Med (2007) 5.48
Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med (2008) 5.23
Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res (2009) 5.10
Efficient magnetic cell labeling with protamine sulfate complexed to ferumoxides for cellular MRI. Blood (2004) 4.66
Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood (2003) 4.43
Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. J Immunol (2006) 4.43
Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med (2000) 4.37
A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology (2008) 4.23
Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res (2009) 4.16
Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin Cancer Res (2007) 3.66
Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. J Immunol (2009) 3.23
Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. Eur J Immunol (2010) 3.18
The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res (2009) 3.18
Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells. J Immunol (1998) 3.03
Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene Ther (2004) 2.97
Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation. J Immunol (1999) 2.94
Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice. Blood (2008) 2.72
Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function. Blood (2007) 2.65
IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients. J Immunol (2009) 2.64
Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure. Cancer Res (1975) 2.54
Highly efficient endosomal labeling of progenitor and stem cells with large magnetic particles allows magnetic resonance imaging of single cells. Blood (2003) 2.50
Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology (2009) 2.45
Synergistic antitumor effects of immune cell-viral biotherapy. Science (2006) 2.37
Gradient echo acquisition for superparamagnetic particles with positive contrast (GRASP): sequence characterization in membrane and glass superparamagnetic iron oxide phantoms at 1.5T and 3T. Magn Reson Med (2006) 2.09
Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14⁻/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer. J Cancer Res Clin Oncol (2010) 1.94
Purging metastases in lymphoid organs using a combination of antigen-nonspecific adoptive T cell therapy, oncolytic virotherapy and immunotherapy. Nat Med (2007) 1.74
Paired immunoglobin-like receptor-B regulates the suppressive function and fate of myeloid-derived suppressor cells. Immunity (2011) 1.72
Hepatic cellular distribution and degradation of iron oxide nanoparticles following single intravenous injection in rats: implications for magnetic resonance imaging. Cell Tissue Res (2004) 1.69
Modulators of arginine metabolism support cancer immunosurveillance. BMC Immunol (2009) 1.61
Oncolytic vesicular stomatitis virus for treatment of orthotopic hepatocellular carcinoma in immune-competent rats. Cancer Res (2003) 1.50
Systemic therapy of experimental breast cancer metastases by mutant vesicular stomatitis virus in immune-competent mice. Cancer Gene Ther (2005) 1.43
Cooperation of B cells and T cells is required for survival of mice infected with vesicular stomatitis virus. Int Immunol (1997) 1.35
The earliest events in vesicular stomatitis virus infection of the murine olfactory neuroepithelium and entry of the central nervous system. Virology (1995) 1.32
Facilitated monocyte-macrophage uptake and tissue distribution of superparmagnetic iron-oxide nanoparticles. PLoS One (2009) 1.31
Safety studies on intrahepatic or intratumoral injection of oncolytic vesicular stomatitis virus expressing interferon-beta in rodents and nonhuman primates. Hum Gene Ther (2010) 1.18
Enhanced oncolytic potency of vesicular stomatitis virus through vector-mediated inhibition of NK and NKT cells. Cancer Gene Ther (2008) 1.17
Use of biological therapy to enhance both virotherapy and adoptive T-cell therapy for cancer. Mol Ther (2008) 1.16
rVSV(M Delta 51)-M3 is an effective and safe oncolytic virus for cancer therapy. Hum Gene Ther (2008) 1.13
Use of macrophages to target therapeutic adenovirus to human prostate tumors. Cancer Res (2011) 1.12
Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma. Proc Natl Acad Sci U S A (1996) 1.10
Oncolysis of hepatic metastasis of colorectal cancer by recombinant vesicular stomatitis virus in immune-competent mice. Mol Ther (2003) 1.09
Mesenchymal stem cells as therapeutic delivery vehicles targeting tumor stroma. Cancer Biother Radiopharm (2011) 0.86
Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med (2006) 15.04
Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res (2006) 7.02
Development of definitive endoderm from embryonic stem cells in culture. Development (2004) 4.61
The terminology issue for myeloid-derived suppressor cells. Cancer Res (2007) 4.37
The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res (2009) 3.18
Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res (2005) 2.91
Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function. Blood (2007) 2.65
FoxO1 mediates insulin-dependent regulation of hepatic VLDL production in mice. J Clin Invest (2008) 2.16
Inhibition of Foxo1 function is associated with improved fasting glycemia in diabetic mice. Am J Physiol Endocrinol Metab (2003) 2.06
Interleukin 10 suppresses Th17 cytokines secreted by macrophages and T cells. Eur J Immunol (2008) 2.05
Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer. Cancer Res (2009) 2.02
Foxo1 mediates insulin action on apoC-III and triglyceride metabolism. J Clin Invest (2004) 1.93
Role of immature myeloid Gr-1+ cells in the development of antitumor immunity. Cancer Res (2004) 1.85
Elevated vascular endothelial growth factor production in islets improves islet graft vascularization. Diabetes (2004) 1.85
Inhibitory receptors bind ANGPTLs and support blood stem cells and leukaemia development. Nature (2012) 1.75
Development and function of myeloid-derived suppressor cells generated from mouse embryonic and hematopoietic stem cells. Stem Cells (2010) 1.75
Paired immunoglobin-like receptor-B regulates the suppressive function and fate of myeloid-derived suppressor cells. Immunity (2011) 1.72
Lymphatic vasculature mediates macrophage reverse cholesterol transport in mice. J Clin Invest (2013) 1.57
Monocytic suppressive cells mediate cardiovascular transplantation tolerance in mice. J Clin Invest (2010) 1.55
Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology (2005) 1.47
Aberrant Forkhead box O1 function is associated with impaired hepatic metabolism. Endocrinology (2006) 1.46
Ischemic colitis after endovascular aortoiliac aneurysm repair: a 10-year retrospective study. Arch Surg (2009) 1.43
Myeloid-derived suppressor cells prevent type 1 diabetes in murine models. J Immunol (2010) 1.38
Extracellular TNFR1 release requires the calcium-dependent formation of a nucleobindin 2-ARTS-1 complex. J Biol Chem (2006) 1.36
An ATF2-derived peptide sensitizes melanomas to apoptosis and inhibits their growth and metastasis. J Clin Invest (2002) 1.35
Targeting immune suppressing myeloid-derived suppressor cells in oncology. Crit Rev Oncol Hematol (2010) 1.25
Pretreatment frequency of circulating IL-17+ CD4+ T-cells, but not Tregs, correlates with clinical response to whole-cell vaccination in prostate cancer patients. Int J Cancer (2009) 1.24
Increased hepatic levels of the insulin receptor inhibitor, PC-1/NPP1, induce insulin resistance and glucose intolerance. Diabetes (2005) 1.24
Molecular surveillance for drug-resistant Plasmodiumfalciparum malaria in Malawi. Acta Trop (2007) 1.23
Exponential enhancement of oncolytic vesicular stomatitis virus potency by vector-mediated suppression of inflammatory responses in vivo. Mol Ther (2007) 1.19
NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation. Int J Cancer (2004) 1.17
Viral and host cofactors facilitate HIV-1 replication in macrophages. J Leukoc Biol (2003) 1.17
OX40 ligation enhances primary and memory cytotoxic T lymphocyte responses in an immunotherapy for hepatic colon metastases. Mol Ther (2002) 1.13
rVSV(M Delta 51)-M3 is an effective and safe oncolytic virus for cancer therapy. Hum Gene Ther (2008) 1.13
Polarization and reprogramming of myeloid-derived suppressor cells. J Mol Cell Biol (2013) 1.12
DNA vaccines delivered by human papillomavirus pseudovirions as a promising approach for generating antigen-specific CD8+ T cell immunity. Cell Biosci (2011) 1.11
Gold nanocrystal labeling allows low-density lipoprotein imaging from the subcellular to macroscopic level. ACS Nano (2013) 1.07
Therapy of falciparum malaria in sub-saharan Africa: from molecule to policy. Clin Microbiol Rev (2004) 1.06
Tumor-expressed inducible nitric oxide synthase controls induction of functional myeloid-derived suppressor cells through modulation of vascular endothelial growth factor release. J Immunol (2012) 1.05
In vitro antimalarial susceptibility profile and prcrt/pfmdr-1 genotypes of Plasmodium falciparum field isolates from Malawi. Am J Trop Med Hyg (2007) 1.01
Rejection of metastatic 4T1 breast cancer by attenuation of Treg cells in combination with immune stimulation. Mol Ther (2007) 0.99
Malaria chemotherapy. Adv Parasitol (2006) 0.99
Laparoendoscopic single site (LESS) splenectomy with a conventional laparoscope and instruments. JSLS (2011) 0.97
Notch2 is required for the proliferation of cardiac neural crest-derived smooth muscle cells. Dev Dyn (2008) 0.96
Basal insulin gene expression significantly improves conventional insulin therapy in type 1 diabetic rats. Diabetes (2002) 0.95
Phase II trial of concurrent sunitinib and image-guided radiotherapy for oligometastases. PLoS One (2012) 0.95
Review of the pathogenesis, diagnosis, and management of type I gastric carcinoid tumor. World J Surg (2011) 0.94
Quantification of renal perfusion using an intravascular contrast agent (part 1): results in a canine model. Magn Reson Med (2003) 0.93
Regulation of dendritic cell function by NK cells: mechanisms underlying the synergism in the combination therapy of IL-12 and 4-1BB activation. J Immunol (2004) 0.93
Functional genomic analysis of type II IL-1beta decoy receptor: potential for gene therapy in human arthritis and inflammation. J Immunol (2002) 0.93
HDL as a contrast agent for medical imaging. Clin Lipidol (2009) 0.92
Concurrent sunitinib and stereotactic body radiotherapy for patients with oligometastases: final report of a prospective clinical trial. Target Oncol (2013) 0.91
Long-term follow-up of patients with fulminant Clostridium difficile colitis. J Gastrointest Surg (2009) 0.91
Myeloid-derived suppressor cells: natural regulators for transplant tolerance. Hum Immunol (2010) 0.91
Cell based cancer vaccines: regulatory and commercial development. Vaccine (2007) 0.88
Specific microtubule-depolymerizing agents augment efficacy of dendritic cell-based cancer vaccines. J Biomed Sci (2011) 0.86
Retrograde intussusception seven years after a laparoscopic Roux-en-Y gastric bypass. J Minim Access Surg (2013) 0.86
In situ recruitment of antigen-presenting cells by intratumoral GM-CSF gene delivery. Cancer Immunol Immunother (2003) 0.85
Frequency and significance of IgG4 immunohistochemical staining in liver explants from patients with primary sclerosing cholangitis. Int J Exp Pathol (2014) 0.85
Establishing an international training program for surgical residents. J Surg Educ (2007) 0.85
Pulsed radiofrequency for chronic testicular pain-a preliminary report. Pain Med (2009) 0.84
IFN-gamma sensitization of prostate cancer cells to Fas-mediated death: a gene therapy approach. Mol Ther (2003) 0.84
The cardiomyocyte lineage is critical for optimization of stem cell therapy in a mouse model of myocardial infarction. FASEB J (2009) 0.84
Specific Dioscorea Phytoextracts Enhance Potency of TCL-Loaded DC-Based Cancer Vaccines. Evid Based Complement Alternat Med (2013) 0.84
Coexisting rectal and urachal carcinoma: a case report. Am J Clin Oncol (2009) 0.84
R-Ras is required for murine dendritic cell maturation and CD4+ T-cell priming. Blood (2011) 0.83
A functional recombinant human 4-1BB ligand for immune costimulatory therapy of cancer. J Immunother (2011) 0.82
Prognostic clinicopathologic factors in longitudinally followed patients with metastatic small bowel carcinoid tumors. Pancreas (2011) 0.82
Sweat gland carcinoma. Am Surg (2004) 0.82
Ultra scale-down studies of the effect of shear on cell quality; Processing of a human cell line for cancer vaccine therapy. Biotechnol Prog (2009) 0.82
Advancements in immune tolerance. Adv Drug Deliv Rev (2007) 0.82
Inflammatory bowel disease: MR- and SPECT/CT-based macrophage imaging for monitoring and evaluating disease activity in experimental mouse model--pilot study. Radiology (2014) 0.81
Sub-population analysis of human cancer vaccine cells--ultra scale-down characterization of response to shear. Biotechnol Bioeng (2010) 0.81
Natural cures for type 1 diabetes: a review of phytochemicals, biological actions, and clinical potential. Curr Med Chem (2013) 0.81
Adenovirus-mediated expression of glucokinase in the liver as an adjuvant treatment for type 1 diabetes. Hum Gene Ther (2002) 0.80
Cecal bascule after laparoscopic ventral hernia repair. JSLS (2013) 0.80
Combined Inhibition of Epidermal Growth Factor Receptor and Cyclooxygenase-2 as a Novel Approach to Enhance Radiotherapy. J Cell Sci Ther (2011) 0.79
The potential of recombinant vesicular stomatitis virus-mediated virotherapy against metastatic colon cancer. Int J Mol Med (2012) 0.79
Determination of ranitidine in urine by capillary electrophoresis-electrochemiluminescent detection. J Chromatogr B Analyt Technol Biomed Life Sci (2006) 0.79